Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewEndocrinologyNeuroscience Open Access | 10.1172/jci.insight.162468

Isradipine therapy in Cacna1dIle772Met/+ mice ameliorates primary aldosteronism and neurologic abnormalities

Gabriel Stölting,1 Hoang An Dinh,1 Marina Volkert,1 Nicole Hellmig,1 Julia Schewe,1 Luise Hennicke,1 Eric Seidel,1 Herbert Oberacher,2 Junhui Zhang,3 Richard P. Lifton,4 Iris Urban,5 Melissa Long,6 Marion Rivalan,6 Timothy Nottoli,7 and Ute I. Scholl1

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Stölting, G. in: JCI | PubMed | Google Scholar |

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Dinh, H. in: JCI | PubMed | Google Scholar |

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Volkert, M. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Hellmig, N. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Schewe, J. in: JCI | PubMed | Google Scholar |

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Hennicke, L. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Seidel, E. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Oberacher, H. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Zhang, J. in: JCI | PubMed | Google Scholar |

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Lifton, R. in: JCI | PubMed | Google Scholar |

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Urban, I. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Long, M. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Rivalan, M. in: JCI | PubMed | Google Scholar

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Nottoli, T. in: JCI | PubMed | Google Scholar |

1Center of Functional Genomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

2Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria

3Nephrology, Yale University School of Medicine, New Haven, United States of America

4Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, United States of America

5Transgenic Technologies, Charité - Universitätsmedizin Berlin, Berlin, Germany

6Animal Outcome Core Facility, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin, Germany

7Yale Gene Editing Center, Yale University School of Medicine, New Haven, United States of America

Find articles by Scholl, U. in: JCI | PubMed | Google Scholar |

Published September 12, 2023 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.162468.
Copyright © 2023, Stölting et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published September 12, 2023 - Version history
View PDF
Abstract

Somatic gain-of-function mutations in the L-type calcium channel CaV1.3 (CACNA1D gene) cause adrenal aldosterone-producing adenomas and micronodules. De novo germline mutations are found in a syndrome of primary aldosteronism, seizures and neurologic abnormalities (PASNA) as well as in autism spectrum disease. Using CRISPR/Cas9, we here generated mice with a Cacna1d gain-of-function mutation found in both adenomas and PASNA syndrome (Cacna1dIle772Met/+). These mice show reduced body weight and increased mortality from weaning to approximately 100 days of age. Male mice do not breed, likely due to neuromotor impairment, and the offspring of female mice die perinatally, likely due to lack of maternal care. Mice generated by in vitro fertilization show elevated intracellular calcium in the aldosterone-producing zona glomerulosa, an elevated aldosterone:renin ratio and persistently elevated serum aldosterone on a high-salt diet as signs of primary aldosteronism. Anesthesia with ketamine and xylazine induces tonic-clonic seizures. Neurologic abnormalities include hyperlocomotion, impaired performance in the rotarod test, impaired nest building and slight changes in social behavior. Intracellular calcium in the zona glomerulosa, aldosterone levels and rotarod performance respond to treatment with the calcium channel blocker isradipine, with implications for the therapy of patients with aldosterone-producing lesions and with PASNA syndrome.

Graphical Abstract
graphical abstract
Supplemental material

View Supplementary Video 1

View Supplementary Video 2

View Supplementary Video 3

View Supplementary Video 4

View

View Supplementary Video 5

Version history
  • Version 1 (September 12, 2023): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts